Skip to main content
. 2014 Nov 11;9(3):586–600. doi: 10.1016/j.molonc.2014.10.011

Table 1.

HER2‐positive tumors – patient characteristics.

Characteristic N (%)
Menopausal status
Premenopausal 34 (44.7)
Postmenopausal 42 (55.3)
Race/Ethnicity
White 65 (85.5)
Asian 1 (1.3)
Hispanic 7 (9.2)
African American 3 (4)
ER
Negative 39 (51.3)
Positive 37 (48.7)
PR
Negative 40 (52.6)
Positive 36 (47.4)
Response to trastuzumab‐based chemotherapy
Stable disease 29 (38.2)
Partial response 21 (27.6)
Progressive disease 26 (34.2)